A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 51
- Registration Number
- NCT03025698
- Locations
- 🇺🇸
Aflac Cancerand Blood Disorders Ctr, Atlanta, Georgia, United States
🇺🇸Phoenix Children s Hospital, Phoenix, Arizona, United States
🇺🇸Arkansas Childrens Hospital, Little Rock, Arkansas, United States
Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 196
- Registration Number
- NCT03020199
- Locations
- 🇬🇧
Novartis Investigative Site, Salford, United Kingdom
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: BYM338 10 mg/kgOther: Placebo
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 78
- Registration Number
- NCT03005288
- Locations
- 🇬🇧
Novartis Investigative Site, Merthyr Tydfil, Mid Glamorgan, United Kingdom
Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT02998645
- Locations
- 🇹🇷
Novartis Investigative Site, Samsun, Turkey
Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne
Phase 2
Completed
- Conditions
- Acne Vulgaris
- Interventions
- Biological: CJM112Other: Placebo
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT02998671
- Locations
- 🇳🇱
Novartis Investigative Site, Leiden, Netherlands
Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet
Phase 2
Completed
- Conditions
- Transfusion-dependent ThalassemiaNon-transfusion-dependent Thalassemia
- Interventions
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 148
- Registration Number
- NCT02993224
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh City, Vietnam
Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma
Phase 1
Completed
- Conditions
- Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
- Interventions
- First Posted Date
- 2016-12-14
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT02992483
- Locations
- 🇺🇸
MD Anderson Cancer Center/University of Texas MD Anderson CC, Houston, Texas, United States
🇪🇸Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain
A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.
- First Posted Date
- 2016-12-12
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT02989402
- Locations
- 🇮🇳
Novartis Investigative Site, Kolkata, West Bengal, India
Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT02988440
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇨🇳Novartis Investigative Site, Taipei, Taiwan
Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02980263